{"id":"ppv-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or erythema"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL2108573","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains purified capsular polysaccharides from multiple serotypes of Streptococcus pneumoniae. These polysaccharide antigens trigger B-cell responses and antibody production, conferring humoral immunity against invasive pneumococcal disease. The vaccine is typically administered to high-risk populations including elderly individuals and those with compromised immune systems.","oneSentence":"PPV vaccine stimulates the immune system to produce antibodies against pneumococcal polysaccharide antigens, providing protection against Streptococcus pneumoniae infection.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:02:00.714Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive pneumococcal disease caused by Streptococcus pneumoniae"},{"name":"Prevention of pneumococcal pneumonia in at-risk populations"}]},"trialDetails":[{"nctId":"NCT03650114","phase":"PHASE3","title":"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2018-12-28","conditions":"Relapsing Multiple Sclerosis","enrollment":1882},{"nctId":"NCT00622843","phase":"PHASE3","title":"Pneumococcal Conjugate Vaccination in HIV in Comparison to Polysaccharide Vaccine Boosting","status":"COMPLETED","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2002-12","conditions":"HIV Infections, Streptococcus Pneumoniae","enrollment":275},{"nctId":"NCT02545868","phase":"PHASE3","title":"A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-10-27","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":102},{"nctId":"NCT05477693","phase":"PHASE4","title":"Immunogenicity and Safety of 23-valent Pneumococcal Polysaccharide Vaccine","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2022-10-25","conditions":"Pneumococcal Infections","enrollment":1800},{"nctId":"NCT04989465","phase":"PHASE4","title":"A Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2021-09-10","conditions":"Pneumococcal Infections","enrollment":600},{"nctId":"NCT00257127","phase":"NA","title":"Immune System Function Following Vaccination in HIV Infected Children Taking Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-02","conditions":"HIV Infections","enrollment":101},{"nctId":"NCT03039491","phase":"EARLY_PHASE1","title":"Immune Response to Pneumococcal Vaccination in Aging HIV Positive Adults","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2015-09-01","conditions":"HIV Lipodystrophy, Aging","enrollment":160},{"nctId":"NCT00304382","phase":"PHASE4","title":"Humoral Determinants of Immunity to Pneumococcal Infection","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2003-01-01","conditions":"Pneumonia, Pneumococcal Infections, Infections, Streptococcus Pneumoniae","enrollment":114},{"nctId":"NCT02451969","phase":"PHASE3","title":"Safety and Immunogenicity Study of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Children, Adults and Elderly","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2015-04","conditions":"Pneumococcal Infections","enrollment":1760},{"nctId":"NCT03095326","phase":"PHASE4","title":"Pneumococcal Vaccination for Splenectomised Thalassemia Major Patients in Indonesia","status":"COMPLETED","sponsor":"Fakultas Kedokteran Universitas Indonesia","startDate":"2013-09-01","conditions":"Thalassemia, Pneumococcal Infection","enrollment":56},{"nctId":"NCT00239694","phase":"PHASE4","title":"PPV: Pneumococcal Polysaccharide Vaccine in Older Adults","status":"COMPLETED","sponsor":"National Institute on Aging (NIA)","startDate":"2001-04","conditions":"Aging","enrollment":100},{"nctId":"NCT00919321","phase":"PHASE4","title":"The Duration of Humoral Immunity and the Memory Cell Function After Vaccination With 7-valent Pneumococcal Conjugate Vaccine in CLL","status":"COMPLETED","sponsor":"Tampere University Hospital","startDate":"2009-06","conditions":"Chronic Lymphocytic Leukemia (CLL)","enrollment":32},{"nctId":"NCT01767402","phase":"PHASE1","title":"Study to Evaluate Safety, Reactogenicity and Immunogenicity of the Pneumococcal Protein PhtD Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-10","conditions":"Pneumococcal Disease","enrollment":150},{"nctId":"NCT01414504","phase":"PHASE2","title":"Pneumococcal Conjugate Vaccine Followup","status":"COMPLETED","sponsor":"William Pomat","startDate":"2009-12","conditions":"Immune Tolerance","enrollment":280},{"nctId":"NCT01402245","phase":"PHASE4","title":"Targeting of Immune Response After Pneumococcal Vaccination","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"2005-01","conditions":"Pneumococcal Pneumonia","enrollment":42},{"nctId":"NCT00148824","phase":"PHASE2","title":"Antibody Responses to Pneumococcal Vaccines Among HIV-Infected Adults.","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2003-02","conditions":"HIV Infections","enrollment":212}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ARTHROPATHY"},{"count":1,"reaction":"DRY SKIN"},{"count":1,"reaction":"DYSPNOEA"},{"count":1,"reaction":"DYSPNOEA EXERTIONAL"},{"count":1,"reaction":"EXCORIATION"},{"count":1,"reaction":"EXTREMITY CONTRACTURE"},{"count":1,"reaction":"HYPERKERATOSIS"},{"count":1,"reaction":"HYPOAESTHESIA"},{"count":1,"reaction":"JOINT SWELLING"},{"count":1,"reaction":"MASKED FACIES"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Pneumovax®"],"phase":"marketed","status":"active","brandName":"PPV Vaccine","genericName":"PPV Vaccine","companyName":"Fakultas Kedokteran Universitas Indonesia","companyId":"fakultas-kedokteran-universitas-indonesia","modality":"Biologic","firstApprovalDate":"","aiSummary":"PPV vaccine stimulates the immune system to produce antibodies against pneumococcal polysaccharide antigens, providing protection against Streptococcus pneumoniae infection. Used for Prevention of invasive pneumococcal disease (bacteremia, meningitis, pneumonia), Prevention of pneumococcal otitis media and sinusitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}